Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.260 -0.170 (-7.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,091,069
Open 2.405
Bid (Size) 2.280 (200)
Ask (Size) 2.290 (400)
Prev. Close 2.430
Today's Range 2.260 - 2.440
52wk Range 1.085 - 4.530
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-38.3%
-38.3%
1 Month
-9.6%
-9.6%
3 Month
-36.7%
-36.7%
6 Month
+38.7%
+38.7%
1 Year
-47.6%
-47.6%

More News

Read More
News headline image
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Forecasting The Future: 4 Analyst Projections For C4 Therapeutics ↗
Via Benzinga
News headline image
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why C4 Therapeutics Stock Crushed the Market on Monday ↗
Via The Motley Fool
News headline image
Here are the top movers in Monday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
CCCC Revenue Drops 46% ↗
Via The Motley Fool
News headline image
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in Upcoming March Investor Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Via Benzinga
News headline image
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
From C4 Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is C4 Therapeutics, Inc. - Common Stock publicly traded?
Yes, C4 Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does C4 Therapeutics, Inc. - Common Stock trade on?
C4 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for C4 Therapeutics, Inc. - Common Stock?
The ticker symbol for C4 Therapeutics, Inc. - Common Stock is CCCC on the Nasdaq Stock Market
What is the current price of C4 Therapeutics, Inc. - Common Stock?
The current price of C4 Therapeutics, Inc. - Common Stock is 2.260
When was C4 Therapeutics, Inc. - Common Stock last traded?
The last trade of C4 Therapeutics, Inc. - Common Stock was at 12/16/25 04:00 PM ET
What is the market capitalization of C4 Therapeutics, Inc. - Common Stock?
The market capitalization of C4 Therapeutics, Inc. - Common Stock is 110.28M
How many shares of C4 Therapeutics, Inc. - Common Stock are outstanding?
C4 Therapeutics, Inc. - Common Stock has 110M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.